AMPED Outcomes Registry of Post-ED Pain Management
- Conditions
- Soft Tissue InjuriesGouty ArthritisFracturesUreteral ColicDysmenorrhea
- Registration Number
- NCT01626235
- Lead Sponsor
- Radnor Registry Research, Inc
- Brief Summary
Study aims to assess patient-recorded outcomes of pain control medications prescribed in the ER after visits for specific painful injuries/illnesses.
- Detailed Description
Multicenter, observational, prospective, out-of-hospital registry collecting clinical, satisfaction, quality of life, and healthcare resource utilization from subjects discharged after ED care for a specific acute pain syndrome with a clinician-determined analgesic regimen. Subjects are stratified by diagnosis and by regimen based on the treating clinician's judgment. The registry study is independent of ED care and clinician's decision-making.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 843
-
Eligible subjects will meet the following criteria:
-
Eligible diagnoses:
musculoskeletal etiologies: acute extremity fractures sprains/strains acute gouty arthritis visceral etiologies: renal colic dysmenorrhea
-
Age GTE 18 years;
-
Decision to discharge from ED to community already made;
-
Decision to give SPRIX, opioid, OR SPRIX + opioid rescue already made;
-
Treating clinician deems patient appropriate for continued analgesic management as an outpatient for the next 3-5 days;
-
Patient has ready touch-tone (mobile or land line) telephone access, provides number (and back-up number, if possible) and agrees (verbal or written consent as mandated by site) to answer and comply with brief IVR questionnaires daily for next 4 days.
-
-
Eligible subjects will meet none of the following criteria:
- Patient admitted or placed on observation status from ED;
- Patient unwilling or unable to comply with telephonic follow-up;
- Fracture that requires surgical repair (even if at a later date);
- Patient has diagnosis of any chronic pain syndrome;
- Patient already routinely takes NSAID or opioid agent;
- Treating clinician has reasonable suspicion of drug-seeking behavior or noncompliance;
- Nasal abnormality or illness that could affect the absorption of intranasal medication (such as: nasal discharge, rhinitis, acute upper respiratory infection, acute epistaxis, nasal polyp, nasal tumor).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Outcomes of pain control measures 5 days 1. Change in pain score over follow-up interval;
2. Healthcare resource utilization during follow-up interval;
3. Patient satisfaction with therapy;
4. Return to work in employed cohort.
- Secondary Outcome Measures
Name Time Method Satisfaction and Economic Outcomes 5 days 1. Effectiveness of work upon return;
2. Relative adverse effect profiles of three treatment regimens;
3. Compliance with therapy;
4. QOL at conclusion of therapy.
Trial Locations
- Locations (10)
University of Texas HSC at Houston
🇺🇸Houston, Texas, United States
Thomas Jefferson University Hospital
🇺🇸Philadelphia, Pennsylvania, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
University of Oklahoma HSC
🇺🇸Tulsa, Oklahoma, United States
Pennsylvania Hospital
🇺🇸Philadelphia, Pennsylvania, United States
LSU Medical Center
🇺🇸New Orleans, Louisiana, United States
Ben Taub General Hospital
🇺🇸Houston, Texas, United States
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States